Guardant Health, Inc.

GH · Nasdaq · ·

Karşılaştır

$154,85+%0,112 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 5 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: +%2,6
1M: -%5,0

Just reported

Q3 2026 results

From Guardant Health's results release of 5 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$361M
+%36 y/y
+%7,8 q/q
Guided
—
No guide given
EPS, GAAP
Actual
-$0,93
Guided
—
No guide given
Operating income, GAAP
Actual
-$132,8M
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$1,36B – $1,37B+%39 y/y Raised +%1,1

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Guardant Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Seçki
Lab tools & diagnostics
InspectStocks tarafından · 20 companies
Instruments, supplies and testing services for labs, drugmakers and doctors.
Fiyat, 1 yıl
+%21,6
Gelir, 1 yıl
+%7,8
+14
A 8B 8C 2D 1F 1

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Guardant Health, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Guardant Health, Inc.

Guardant Health, Inc.

Q3 2026 results

Revenue

EPS, GAAP